Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models

SGLT2 Deletion Improves Glucose Homeostasis and Preserves Pancreatic β-Cell Function

(2011) Michael J. Jurczak et al.   DIABETES

Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects

(2011) S. Sha et al.   DIABETES OBESITY & METABOLISM

Discovery of Canagliflozin, a NovelC-Glucoside with Thiophene Ring, as Sodium-Dependent Glucose Cotransporter 2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus(1)

(2010) Sumihiro Nomura et al.   JOURNAL OF MEDICINAL CHEMISTRY

SGLT2 Mediates Glucose Reabsorption in the Early Proximal Tubule

(2010) V. Vallon et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

(2010) Clifford J Bailey et al.   LANCET

SGLT2 inhibition — a novel strategy for diabetes treatment

(2010) Edward C. Chao et al.   NATURE REVIEWS DRUG DISCOVERY

Renal glucose transporters: novel targets for hyperglycemia management

(2010) Amanda Mather et al.   Nature Reviews Nephrology

Familial Renal Glucosuria and SGLT2: From a Mendelian Trait to a Therapeutic Target

(2009) R. Santer et al.   Clinical Journal of the American Society of Nephrology

A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers: Applicability of a novel insulin-independent treatment

(2009) J. P.H. Wilding et al.   DIABETES CARE

Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies

(2009) S. Del Prato   DIABETIC MEDICINE

Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats

(2009) Yoshikazu Fujimori et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus

(2009) Sunil Nair et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Renal sodium–glucose transport: role in diabetes mellitus and potential clinical implications

(2009) George L. Bakris et al.   KIDNEY INTERNATIONAL

Mutation of Solute Carrier SLC16A12 Associates with a Syndrome Combining Juvenile Cataract with Microcornea and Renal Glucosuria

(2008) Barbara Kloeckener-Gruissem et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats

(2008) S. Han et al.   DIABETES

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes

(2008) J. F. List et al.   DIABETES CARE

The Role for Endoplasmic Reticulum Stress in Diabetes Mellitus

(2008) Décio L. Eizirik et al.   ENDOCRINE REVIEWS

Na+-Glucose Transporter-2 Messenger Ribonucleic Acid Expression in Kidney of Diabetic Rats Correlates with Glycemic Levels: Involvement of Hepatocyte Nuclear Factor-1α Expression and Activity

(2007) H. S. Freitas et al.   ENDOCRINOLOGY